CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential

CSL Partners with Alentis for $1.6B Autoimmune Drug Deal

CSL has partnered with Swiss biotech Alentis Therapeutics in a deal worth up to $1.6 billion to co-develop and co-promote lixudebart, an investigational anti-claudin-1 therapy. The agreement includes an upfront payment of $355 million and up to $1.2 billion in milestone payments. Lixudebart is currently in Phase 2 development (RENAL trial) for anti-neutrophil cytoplasmic antibodies–associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), a rare autoimmune kidney condition. The collaboration also targets focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC). CSL will fully fund the RENAL trial and a planned Phase 3 study for AAV-RPGN, as well as mid-stage development for FSGS and PSC. Global profits will be split 55% for CSL and 45% for Alentis. The deal excludes idiopathic pulmonary fibrosis (IPF), for which lixudebart received FDA Orphan Drug Designation in May 2024.

• CSL has entered a strategic partnership with Alentis Therapeutics, committing an upfront payment of $355 million and potential milestone payments of up to $1.2 billion, totaling up to $1.6 billion. This collaboration focuses on the co-development and co-promotion of lixudebart for rare kidney and liver conditions, aligning with CSL's strategy to enhance its pipeline through external innovation.
• The investigational drug, lixudebart, is a claudin-1-targeting antibody currently in Phase 2 development (RENAL trial) for anti-neutrophil cytoplasmic antibodies–associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN). The partnership also aims to explore lixudebart's anti-inflammatory and anti-fibrotic benefits for focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC).
• Under the agreement, CSL will fully fund the ongoing Phase 2 RENAL trial and a subsequent planned Phase 3 study for AAV-RPGN, alongside covering costs for lixudebart's mid-stage development in FSGS and PSC. Upon regulatory approval, global profits from any commercialized products will be shared, with CSL receiving 55% and Alentis Therapeutics 45%.

Addressing Unmet Needs in AAV-RPGN Treatment

Current treatment approaches for AAV-RPGN have advanced considerably, yet several clinically significant challenges persist across induction, maintenance, and long-term disease management. The therapeutic landscape is shaped by the dual burden of disease-related organ damage and the toxicity profiles of the immunosuppressive regimens required to achieve and sustain remission.

• Corticosteroid-related toxicity: High-dose, tapering glucocorticoids remain a cornerstone of induction therapy alongside cyclophosphamide or rituximab. Higher cumulative glucocorticoid doses are statistically associated with worse glucocorticoid-related toxicity (P=0.008; 95% CI, 1.31 to 8.05), with adverse features including mood disturbance, glucocorticoid-induced psychosis, adrenal insufficiency, and infection-related events occurring across the treatment timeline. This narrow therapeutic window supports the need for glucocorticoid-sparing treatments.

• Relapse burden and absence of predictive biomarkers: Disease relapse is a consistent feature of AAV; in one long-term paediatric cohort, all patients experienced relapse, with a median of 4 episodes per patient. Therapeutic strategies cannot yet be individually optimised because clinical or biological parameters that predict when a relapse will occur and its severity have not been identified, making it difficult to determine optimal dosing, administration duration, and treatment intensity commensurate with expected relapse severity.

• Treatment-related morbidity over the long term: Immunosuppressive regimens carry substantial cumulative morbidity. In a long-term paediatric follow-up cohort, 7 of 8 patients suffered infections, 4 were infertile, 2 had skeletal complications, and 1 developed malignancy. Late cardiovascular morbidity is also recognised as a major longer-term potential concern for survivors of ANCA vasculitis.

• Limitations of avacopan as an emerging glucocorticoid-sparing option: Avacopan, an oral C5a receptor antagonist approved as adjunctive therapy for severe active ANCA vasculitis, has demonstrated reductions in disease activity, proteinuria, and glucocorticoid exposure, and may allow for greater kidney recovery in patients with severe renal insufficiency. However, additional clinical trials are warranted to identify the optimal dosage and method of use, and further research is needed to better understand long-term safety and how to optimise integration into treatment paradigms. As of April 2026, its marketing authorisation is also undergoing regulatory review by the US Food and Drug Administration and the European Medicines Agency.

• Progression to end-stage renal disease and incomplete renal recovery: Renal involvement in AAV commonly leads to acute kidney injury with hematuria and proteinuria, and validated scores and classifications exist to predict progression toward end-stage renal disease. Even with treatment, renal function outcomes vary; in one case series, only one patient developed end-stage renal failure over long-term follow-up, yet drug-induced AAV cases have resulted in advanced chronic kidney disease or death, underscoring the heterogeneity of renal outcomes and the need for early biopsy-guided risk stratification per KDIGO 2024 guidelines.

CSL's Bold Bet on Claudin-1: Reshaping Rare Disease Treatment

CSL's substantial investment in Alentis Therapeutics and its lead asset, lixudebart, marks a significant strategic maneuver into the challenging landscape of rare autoimmune and fibrotic diseases. This collaboration, centered on an investigational anti-claudin-1 therapy, highlights a growing industry focus on novel mechanisms to address conditions with profound unmet needs.

Lixudebart is currently in Phase 2 development for ANCA-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), a severe kidney condition. While existing treatments like avacopan have demonstrated improved renal outcomes and reduced glucocorticoid toxicity, the AAV landscape still seeks therapies that offer superior efficacy or a more favorable safety profile, particularly for patients who are refractory to current options. The partnership also targets focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC), two conditions where targeted therapeutic options are notably scarce. Research indicates that claudin-1 plays a crucial role in the pathophysiology of both FSGS and PSC, suggesting a strong scientific rationale for this therapeutic approach.

This deal carries several key implications:

• It underscores the industry's confidence in Claudin-1 as a novel therapeutic target, potentially paving the way for a new class of drugs for fibrotic and autoimmune disorders.

• CSL's commitment to fully fund the extensive clinical development, including a planned Phase 3 study for AAV-RPGN, significantly de-risks the program for Alentis and could accelerate lixudebart's path to market.

• The move positions CSL to enter and potentially reshape treatment paradigms in these specialized rare disease markets.

However, the path forward is not without its challenges. Lixudebart will need to demonstrate a compelling efficacy and safety profile in ongoing and future clinical trials, especially when compared to established or emerging therapies in AAV-RPGN. Furthermore, as claudin-1 is integral to barrier function across multiple organ systems, careful monitoring for potential off-target effects will be critical. Despite these considerations, the partnership represents a bold bet on a novel mechanism with the potential to deliver much-needed therapeutic innovation for patients facing severe, progressive diseases.